AMRI and CHDI Foundation entered a collaboration agreement focused on the discovery of new therapies for the treatment of Huntington’s disease (HD). AMRI will test samples from its compound collection against several JNK kinases. These kinases may be involved in the progression of HD. AMRI will use its computer-aided drug discovery (CADD), biological assay development and high throughput screening for this project. “AMRI is pleased to have this opportunity to partner with CHDI in its efforts ...